Page 16 - Patrick Wingrove News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's weight loss treatment, giving the U.S. drugmaker official entry into a lucrative market that has captured Wall Street's enthusiasm this year. The FDA approved tirzepatide for weight loss under the brand name Zepbound. It has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending.

The US Federal Trade Commission on Tuesday said it sent letters to medical device companies and drugmakers disputing the accuracy or relevance of 110 patents that could lead to delays in generic competition.

-The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's drug for weight loss, giving the U.S. drugmaker official entry into a lucrative market that has captured Wall Street's... -November 08, 2023 at 01:59 pm EST - MarketScreener

The U.S. Federal Trade Commission on Tuesday said it sent notice letters to Abbvie, AstraZeneca, Teva and other drugmakers and medical device companies disputing the accuracy or relevance of more...

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability. The two companies have...